Kathy Albain
Has grant
Professor of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Epigenetic Regulation of Cancer Stem Cells: New Targets and Treatments for Resistant Breast Cancer
Open Date: 2026-10-01
Close Date: 2027-09-30
Grant: Close
Mechanistic Insight into Breast Cancer Stem Cell Survival and Resistance to Therapy: Cross-Regulation between Notch4 and DAXX
Open Date: 2024-10-01
Close Date: 2025-09-30
Grant: Close
Mechanistic Insight into Breast Cancer Stem Cell Survival and Resistance to Therapy: Cross-Regulation between Notch4 and DAXX
Open Date: 2023-10-01
Close Date: 2024-09-30
Grant: Close
The role of DAXX as a breast cancer suppressor and predictor of therapeutic response in estrogen receptor-positive and triple negative disease
Open Date: 2020-10-01
Close Date: 2021-09-30
Grant: Close
The role of DAXX as a breast cancer suppressor and predictor of therapeutic response
Open Date: 2019-10-01
Close Date: 2020-09-30
Articles (3)
Breast cancer subtyping is essential for precision oncology, influencing prognosis, treatment selection, and clinical trial design. The Integrative Subtype Classification (IC) categorizes breast tumors into groups with distinct long-term outcomes based on genomic and correlated transcriptomic features. This method relies on sequencing data, which, despite decreasing costs, is not always available in research or clinical settings. Here we introduce PATH-IC, a computational pathology model that predicts ER+ breast cancer IC subtype risk of relapse categories from routine histology data. We enhance the current state-of-the-art computational pathology approach with BERGERON, which leverages generative AI to correct class imbalance and reduce overfitting, showing that synthetic data improves PATH-IC’s performance by the equivalent of 41% more real training samples. PATH-IC achieves a testing AUROC of 0.814, with predictions correlating to Oncotype DX scores and long-term relapse risk. Using attention-based model interpretation and CRAWFORD, a novel embedding-to-image foundation model, we demonstrate that PATH-IC identifies expected tumor microenvironment patterns for IC subtypes and highlights heterochromatin condensation as a key feature of high-risk tumors. Matched single-cell spatial transcriptomics confirm IC subtype-specific gene expression patterns identified by PATH-IC, including active metabolic, proliferative, and proteostasis pathways in the high-risk group. PATH-IC advances computational pathology through generative AI, enabling subtype inference from histopathology data.
Year:
2025
Purpose: The neutralizing peptibody trebananib prevents angiopoietin-1 and angiopoietin-2 from binding with Tie2 receptors, inhibiting angiogenesis and proliferation. Trebananib was combined with paclitaxel±trastuzumab in the I-SPY2 breast cancer trial. Patients and Methods: I-SPY2, a phase II neoadjuvant trial, adaptively randomizes patients with high-risk, early-stage breast cancer to one of several experimental therapies or control based on receptor subtypes as defined by hormone receptor (HR) and HER2 status and MammaPrint risk (MP1, MP2). The primary endpoint is pathologic complete response (pCR). A therapy “graduates” if/when it achieves 85% Bayesian probability of success in a phase III trial within a given subtype. Patients received weekly paclitaxel (plus trastuzumab if HER2-positive) without (control) or with weekly intravenous trebananib, followed by doxorubicin/cyclophosphamide and surgery. Pathway-specific biomarkers were assessed for response prediction. Results: There were 134 participants randomized to trebananib and 133 to control. Although trebananib did not graduate in any signature [phase III probabilities: Hazard ratio (HR)-negative (78%), HR-negative/HER2-positive (74%), HR-negative/HER2-negative (77%), and MP2 (79%)], it demonstrated high probability of superior pCR rates over control (92%–99%) among these subtypes. Trebananib improved 3-year event-free survival (HR 0.67), with no significant increase in adverse events. Activation levels of the Tie2 receptor and downstream signaling partners predicted trebananib response in HER2-positive disease; high expression of a CD8 T-cell gene signature predicted response in HR-negative/HER2-negative disease. Conclusions: The angiopoietin (Ang)/Tie2 axis inhibitor trebananib combined with standard neoadjuvant therapy increased estimated pCR rates across HR-negative and MP2 subtypes, with probabilities of superiority >90%. Further study of Ang/Tie2 receptor axis inhibitors in validated, biomarker-predicted sensitive subtypes is warranted.
Year:
2024
Purpose: The neutralizing peptibody trebananib prevents angiopoietin-1 and angiopoietin-2 from binding with Tie2 receptors, inhibiting angiogenesis and proliferation. Trebananib was combined with paclitaxel±trastuzumab in the I-SPY2 breast cancer trial. Patients and Methods: I-SPY2, a phase II neoadjuvant trial, adaptively randomizes patients with high-risk, early-stage breast cancer to one of several experimental therapies or control based on receptor subtypes as defined by hormone receptor (HR) and HER2 status and MammaPrint risk (MP1, MP2). The primary endpoint is pathologic complete response (pCR). A therapy “graduates” if/when it achieves 85% Bayesian probability of success in a phase III trial within a given subtype. Patients received weekly paclitaxel (plus trastuzumab if HER2-positive) without (control) or with weekly intravenous trebananib, followed by doxorubicin/cyclophosphamide and surgery. Pathway-specific biomarkers were assessed for response prediction. Results: There were 134 participants randomized to trebananib and 133 to control. Although trebananib did not graduate in any signature [phase III probabilities: Hazard ratio (HR)-negative (78%), HR-negative/HER2-positive (74%), HR-negative/HER2-negative (77%), and MP2 (79%)], it demonstrated high probability of superior pCR rates over control (92%–99%) among these subtypes. Trebananib improved 3-year event-free survival (HR 0.67), with no significant increase in adverse events. Activation levels of the Tie2 receptor and downstream signaling partners predicted trebananib response in HER2-positive disease; high expression of a CD8 T-cell gene signature predicted response in HR-negative/HER2-negative disease. Conclusions: The angiopoietin (Ang)/Tie2 axis inhibitor trebananib combined with standard neoadjuvant therapy increased estimated pCR rates across HR-negative and MP2 subtypes, with probabilities of superiority >90%. Further study of Ang/Tie2 receptor axis inhibitors in validated, biomarker-predicted sensitive subtypes is warranted.
Year:
2024
Collaborators (25)
Nola Hylton
Professor
University of California, San Francisco
Lajos Pusztai
Yale University
Michelle Melisko
Clinical Professor of Medicine
University of California, San Francisco
Amy Clark
Assistant Professor of Medicine
University of Pennsylvania
Amy Jo Chien
Professor of Clinical Medicine Medical Director, Breast Oncology
University of California, San Francisco
Sarah Blair
Professor
UC San Diego Health System
Angela DeMichele
University of Pennsylvania
W. Fraser Symmans
Professor
The University of Texas MD Anderson Cancer Center
Corey W. Speers
Professor and Chair with Tenure
University of Michigan
Julie E. Lang
University of Southern California
Rita Nanda
Associate Professor of Medicine; Director Breast Oncology
University of Chicago
Hope Rugo
Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology
City Of Hope National Medical Center
Yunn-Yi Chen
Professor
UCSF Medical Center
Erica M. Stringer-Reasor
Associate Professor
The University of Alabama
Gillian Hirst
Associate Professor
University of California, San Francisco
Christina Curtis
Professor of Medicine & Genetics
Stanford University
Rosa Isela Gallagher
Senior Research Scientist
George Mason University
Douglas Yee
Professor
University of Minnesota
Laura Esserman
University of California
Claudine Isaacs
Professor of Medicine
Georgetown University
Cansu Karakas
Assistant Professor (University Medical Line)
Stanford University Medical Center
Laura J. van 't Veer
University of California, San Francisco
miguel quintela-fandino
Director
Universidad Autónoma de Madrid
LAMORNA SWIGART
University of California, San Francisco
David Potter
Associate Professor
University of Minnesota
Make your next move.
Prepare your application
Review drafts before you send them.